Outcome of the 247th meeting of the Board of Directors held today, i.e, Wednesday, July 29, 2026.

Novartis India Limited July 29, 2026 The Secretary, BSE Limited, Phiroze Jejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 500672. Dear Sir / Ma’am, Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”) Ref: Outcome of 247th meeting of the Board of Directors held on July 29, 2026 and other disclosures. 1. Pursuant to the agreement for the sale and purchase of the Sale Shares in Novartis India Limited dated February 19, 2026 entered into by and amongst Novartis AG (“NAG”), WaveRise Investments Limited (“WaveRise”), ChrysCapital Fund X (“Fund X”) and Two Infinity Partners (“TIP”, and together with WaveRise and Fund X, “CC”), the sale of 17,450,680 equity shares of the Company from NAG to CC (the “Transaction”) has been completed today, i.e., July 29, 2026. 2. The board of directors of the Company (“Board”), at its 247th meeting held on July 29, 2026, has inter-alia, considered, approved and resolved as follows: A. To consider and approve the execution of various business agreements The Board has approved the execution of the following agreements: (i) Tegrital Brand License Deed dated July 29, 2026 executed between Novartis AG and the Company (“BLA”), pursuant to which Novartis AG has agreed to license and subsequently assign the “TEGRITAL” trademark to the Company in accordance with the terms and conditions set out in the BLA. The details required pursuant to Regulation 30 of the Listing Regulations read with the master circular for compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 by listed entities dated July 11, 2023 (as updated on January 30, 2026) issued by Securities and Exchange Board of India (“SEBI Master Circular”), is enclosed in Annexure I; (ii) distribution agreement dated July 29, 2026 executed between Novartis Pharma Services AG and the Company (“Distribution Agreement”), pursuant to which the Company has agreed to be appointed as the distributor by Novartis Pharma Services AG in India, to import and distribute certain products (as set out in the Distribution Agreement), in accordance with the terms and conditions provided in the Distribution Agreement. The details required pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular is enclosed in Annexure II; and Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited (iii) Trademark Assignment and License Deed dated July 29, 2026 executed between Novartis AG and the Company (“TMLA”), pursuant to which the Company has been assigned certain trade marks and logos, (as set out in the TMLA) by Novartis AG, in accordance with the terms and conditions provided in the TMLA. The details required pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular is enclosed in Annexure III. B. Appointment of Key Managerial Personnel The Board has approved: (i) the appointment of Dr. Vikas Gupta (DIN: 10704329), as the Additional Director and Chief Executive Officer of the Company, with effect from July 29, 2026, pursuant to the recommendations of the nomination and remuneration committee of the Company and subject to approval of the shareholders of the Company; (ii) the change in designation of Dr. Vikas Gupta (DIN: 10704329), from Additional Director and Chief Executive Officer of the Company to Managing Director and Chief Executive officer with effect from July 29, 2026, pursuant to the recommendations of the nomination and remuneration committee of the Company and subject to approval of the shareholders of the Company; and (iii) the appointment of Mr. Bhagwat Singh Deora, as the Chief Financial Officer of the Company, with effect from July 29, 2026, pursuant to the recommendations of the nomination and remuneration committee and audit committee of the Company. The details required pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular is enclosed in Annexure IV C. Adoption and/or revision of various corporate policies and codes of the Company The Company has considered and adopted the following policies: (i) Vigil Mechanism and Whistleblower Policy; (ii) Corporate Social Responsibility Policy; (iii) Policy on Preservation of Documents; (iv) Nomination and Remuneration Committee Policy; (v) Risk Management Policy; (vi) Policy for Determination of Materiality of Events or Information; (vii) Code of Practices & Procedures for Fair Disclosure of UPSI; (viii) Policy on Materiality of Related Party Transactions; and (ix) Grievance Redressal Policy; (x) Code of Conduct for Board of Directors and Senior Management; (xi) Code of Conduct to Regulate, Monitor and Report Insider Trading; and (xii) Board Familiarization Programme. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited D. To take note of the change in email domain and migration to the new corporate email system Pursuant to the completion of the Transaction and the consequent change in control of the Company, the Company adopted a new corporate email domain (i.e., nilpharma.co.in) in line with the branding, information technology and cybersecurity requirements of the new management of the Company. E. To take note of the launch and adoption of the new website of the Company Pursuant to the completion of the Transaction and the consequent change in control of the Company, the Company adopted a new website (i.e., https://www.nilpharma.co.in) incorporating the revised branding, corporate information and disclosures as required under applicable law. F. Reconstitution of Committees The risk management committee and stakeholders relationship committee of the board of the Company have been re-constituted due to appointment and resignation of directors, in compliance with the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The details of the re-constituted committees is set forth in Annexure V. 3. In addition, the following Senior Management Personnel have been appointed to the Company, with effect from July 29, 2026: (i) Mr. Jason D’Souza as the President – M&A, Business Development & Investor Relations; (ii) Mr. Rahul Vijayvargiya as the Chief Human Resource Officer (CHRO); (iii) Mr. Masud Shaikh as the Chief Supply Chain Officer; and (iv) Mr. Sumeet Rajput as the President - Business Operations. The details required pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular is enclosed in Annexure VI. The meeting of the Board commenced at 07.15 P.M. and concluded at 08.30 P.M. Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited The above is for your information and the same is also available on the website of the Company i.e. www.nilpharma.co.in Yours faithfully, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer Encl.: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis India Limited Annexure I Tegrital Brand License Deed executed between Novartis AG and the Company Particulars Details Name( [Showing first 8,000 characters — download PDF for full document]